AZD0780 + AZD4954 for Healthy Subjects

Overseen By AstraZeneca Clinical Study Information Center

Age: 18 - 65

Sex: Any

Trial Phase: Phase 1

Sponsor: AstraZeneca

Must not be taking: Lipid-lowering therapy

Disqualifiers: Gastrointestinal, Hepatic, Renal, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

32 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.

Are You a Good Fit for This Trial?

Inclusion Criteria

* Have a body mass index between 18 and 35 kg/m2 inclusive and weigh at least 50 kg.

I am not breastfeeding and will use effective birth control if I could become pregnant.

I am a woman who is postmenopausal or permanently sterile from surgery (not tubal ligation).

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Period 1

Participants receive a single dose of either AZD4954 or laroprovstat alone

1 week

1 visit (in-person)

Treatment Period 2

Participants receive single doses of laroprovstat + AZD4954

1 week

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 6 weeks

Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• AZD0780
• AZD4954

How Is the Trial Designed?

Group I: Cohort 2: Treatment Sequence BC Experimental Treatment 2 Interventions

Participant will receive single dose of laroprovstat alone (Treatment B) followed by single doses of laroprovstat+AZD4954 (Treatment C).

Group II: Cohort 1: Treatment Sequence AC Experimental Treatment 2 Interventions

Participant will receive single dose of AZD4954 alone (Treatment A) followed by single doses of laroprovstat+AZD4954 (Treatment C).

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology